Reading an interaction checker output critically posts 91–120
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
My experience of reading an interaction checker output contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
If anyone can point at the primary source I would be grateful.
Taking post #92 at face value and following it one step further.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
I would rather post the uncertainty than round it away.
Supplements and herbs: many have no established interaction. Some do. If you are taking something unusual, checking a reference (like a pharmacist) is more useful than guessing from forum discussion.
Gastrointestinal symptoms from one compound can mask or mimic an interaction with another. Introducing two changes at once makes attribution impossible, which is an argument for spacing them.
None of the above is medical advice and I am not qualified to give any.
This follows post #95 rather than contradicting it.
Worth separating reading an interaction checker output as a question about the compound from reading an interaction checker output as a question about the documentation. They get answered by different people and only one of them is answerable here.
Post #95 describes the usual case. This is about the unusual one.
Vitamins: most vitamins have no significant interaction. Fat-soluble vitamins (A, D, E, K) might be affected by the slowing of fat absorption during weight loss, but that is a nutritional consequence rather than an interaction.
If that reads as pedantic, it is, and it has saved me twice.
Adding the measurement that post #99 says would settle it.
A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is usually worse rather than better.
One of those cases where knowing the mechanism does not help the decision.
Adding the measurement that post #99 says would settle it.
The most useful reply I ever got about reading an interaction checker output was a request to state my units. It sounds like pedantry and it has saved me twice.
I had written a reply contradicting post #99 and deleted it. Here is what survived.
Anyone asking an interaction question should list everything, including the things they consider irrelevant. The irrelevant one is the answer more often than chance would suggest.
A single observation, in a thread that deserves better than single observations.
Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the combination carries hypoglycemia risk if insulin doses are not adjusted. That is a reason for close monitoring, not for avoiding the combination.
I would be glad to be shown a cleaner way of putting this.
Answering the question post #103 raises rather than the one it answers.
Absence of an interaction study is not evidence of no interaction. A great many combinations discussed here have simply never been studied, and saying so is more useful than reasoning from mechanism alone.
The arithmetic in post #103 is right; the assumption feeding it is the part to check.
Research-use-only compounds have no interaction data of any kind, because interaction studies are done on medicines being developed for use in people.
I am not the right person to answer the follow-up to this.
Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
That is one dataset and I would not build a rule on it.
Nothing to add on the substance. Thank you for taking the question at face value.
Anticoagulants: no direct interaction with the compounds in this class. Weight loss and body composition changes might affect the clearance or effect of warfarin if you are on it; monitoring INR more frequently during weight loss is reasonable.
That is all the detail I have. Someone else will have more.
On reading an interaction checker output, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
Oral medications with a narrow therapeutic index are the ones where that matters most. The interaction is about rate and timing rather than about the total absorbed, in most published cases.
The variance between people here is larger than the effect being discussed.
Collapsed as off-topic by two members at trust level 3 or above
The arithmetic in post #114 is right; the assumption feeding it is the part to check.
Insulin and sulfonylureas are the interaction that the labelling in this class flags most explicitly, because the risk is additive glucose lowering. That is a prescribing question and not a forum question.
Alcohol is not contraindicated in the labelling and it does irritate a stomach that is already emptying slowly. There is no published interaction study, and the conservative reading is the obvious one.
Separation timing versus clinically important interaction: a separation timing inconvenience (taking one medication 2 hours before or after another) is not the same as a clinically important interaction. Both can reduce absorption of one or the other, but only true interactions require active management.
Take it as a starting point and not as a specification.
Where a published interaction study exists it usually reports an area-under-curve ratio, and that number is far more informative than a yes-or-no answer.
I looked this up rather than remembered it, which is the right order.
Anything that also slows gut motility compounds the same mechanism. That is a plausibility argument rather than a documented interaction, and it should be labelled as one.
The general case is well covered; this is the awkward specific one.